The goal of deploying two new antiviral drugs to prevent and treat COVID-19 by year end, as set by the UK Government, might not be as far-fetched as it sounds, according to plans and trials already underway said experts in the fields of virology and pharmaceuticals at a media briefing last week.
To meet the Governments challenge, antiviral drugs active against SARS-CoV-2 would most likely be administered orally, intranasally or inhaled; already be at the phase 1 or 2 stage of development or beyond; be for short-term use only; and exhibit targeted anti-viral activity without adversely affecting other parts of the body, said Ruth McKernan, PhD, chair of the BioIndustry Association. "Any drug that has more complicated administration, or has longer use, will have too high hurdles to jump," she highlighted.
A handful of candidate drugs meet these criteria and include favipiravir, niclosamide, iota-carrageenan, and molnupiravir, among others.
Despite a successful vaccination programme in the UK, there remains a pressing need for antiviral drugs to plug the gap between those protected via vaccination and those in whom vaccinations are ineffective, vaccination is contraindicated, or who choose to opt out of vaccination. New variant escape from vaccine protection also presents a threat and is likely to persist for some time to come.
Most pharmaceuticals take around 15 years from concept to market, but this development time is approximately halved in antiviral drugs, said McKernan. "The making of antivirals, along with anti-bacterial drugs has a higher probability of success than most other pharmaceuticals."
She also noted that the availability of human challenge studies where volunteers are purposefully infected with SARS-CoV-2 for study purposes were "hugely enabling" and were key given that case numbers limited the availability of trial volunteers, although there remains the possibility of conducting trials in countries with higher incidence of COVID-19.
Speaking alongside McKernan was Dr Ian Hall, professor of molecular medicine, University of Nottingham. He explained that successful candidate drugs would need to take effect early in disease where the drugs would be more effective. "Essentially, administration would be community based, so as soon as a positive test confirms infection, or as a prophylaxis in people notified as having been in contact with a positive individual. Other likely users will be those who become infected via nosocomial spread in hospitals who often have worse outcomes due to other conditions, and subgroups such as patients with haematological malignancies who typically have worse outcomes."
McKernan added that here in the UK, with government support and enablement, vaccine development had provided a good example of how to expedite manufacturing and supply issues. "This is likewise important for antiviral drugs too. In addition, the MHRA [Medicinesand Healthcare products Regulatory Agency] has also shown how it can evaluate products efficiently. However, she drew attention to maintaining a good testing and contact tracing system. "Antivirals work best early on in disease. If you cant detect, you cant treat, so you need a very good testing system."
In April, the Government announced that it was establishing a new Antivirals Taskforce to identify and deploy innovative, home-based, COVID-19 treatments as early as this autumn. Treatments would be taken after testing positive or being exposed to COVID-19 and would be aimed at reducing transmission and speeding up recovery.
Last Thursday, Eddie Gray, previously president of the European Pharmaceutical Business at GlaxoSmithKline, and CEO of Dynavax Technologies, accepted the role as chair of the new COVID-19 Antivirals Taskforce. "I do think the antiviral programme and the story around antivirals is an important one and has a real contribution to make to the overall response to COVID, and I am looking forward to moving that programme forward," he told journalists in a briefing hosted by the Science Media Centre.
Antiviral agents exert activity at the virus level, potentially interfering at one or more mechanistic stages of viral infection, for example, how the virus enters the cell, amplifies, makes new proteins, repackages itself into new viral particles, or bursts out to infect other areas of the body.
McKernan explained that there are four key ways that an anti-SARS-CoV-2 drug might work, in principle. Firstly, a drug can stop the virus entering the cell by interfering with the two main receptors that permit viral entry the angiotensin-converting enzyme (ACE) 2 receptor and/or the serine protease TMPRSS2 used for S protein priming. Secondly, because the virus needs to make new proteins, drugs can target the protein synthesis pathway of the virus specifically. Thirdly, a drug can target enzymes involved in the assembly of new viral particles called protease inhibitors; and fourthly drugs can interfere with RNA synthesis.
Good laboratory-based assays are also needed to test whether the molecules work, McKernan pointed out. "Its also necessary to have molecules that are as selective as possible so they dont interfere with other processes of the human body, making them safe to use."
Safety is essential and preclinical safety studies cannot be rushed, she stressed. "The duration of drug treatment is instrumental in the assessment of safety. If the duration is 5 days to 2-weeks then the safety hurdles are lower than a drug designed for longer duration of use."
Prof Hall is chair of the UK COVID-19 Therapeutics Advisory Panel (UK-CTAP) antiviral sub-panel. UK-CTAP was set up to advance agents most likely to be effective against COVID-19.
He explained that UK-CTAP had overseen 300 approaches with candidate drugs to tackle COVID-19. "Its impossible to study all of these and take them forward so weve strategically prioritised those drugs which have the greatest chance of success. Weve made 15 recommendations to the CMO [Chief Medical Officer] for trials in COVID-19."
The three leading recommendations are: favapiravir, an antiviral drug used for influenza and similar viruses; niclosamide (an oral antihelminthic drug used to treat tapeworm infections and which has shown activity against SARS-CoV-2 in vitro); and iota-carrageenan (a seaweed derivative and nasal spray shown to reduce symptoms of cold and flu, which has demonstrated in vitro activity against SARS-CoV-2).
UK-CTAP has considered 150 agents that currently have insufficient evidence to advance to existing clinical platforms, explained Prof Hall.
He also identified a significant challenge going forward. "To take these drugs forward through clinical trials we need to test them on patients with COVID-19. But since the vaccine strategy has been so successful to date the number of cases available is low and without sufficient cases then it is difficult to prove efficacy and pick up rare side effects."If we see escape variants it would be easier to do trials but the need for these drugs would be greater," he added.
Also in the race is molnupiravir (MK4482), a novel antiviral agent being jointly developed by pharmaceutical companies MSD and Ridgeback Biotherapeutics in the phase 3 MOVe-OUT Study.
"Molnupiravir inhibits a critical step in the replication of SARS-CoV-2, other coronaviruses and multiple RNA viruses. Early phase 2 studies show activity against SARS-CoV-2 and we believe it has potential to be a broad spectrum antiviral drug effective against a range of diverse coronaviruses as well as influenza and RSV [respiratory syncytial virus]," said Dr Daria Hazuda,vice president research, chief scientific officer, MSD.
Preclinical models suggest it can block transmission of SARS-CoV-2. Hazuda explained that based on results of a phase 2 study, the phase 3 trial will now focus on outpatient use because the highest efficacy impact on disease was seen in early community-based infection. Results are expected later in 2021.
The Prophylactic Therapy in Care Homes (NIHR-PROTECT-CH) trial platform is assessing two potential antiviral compounds in one of the most vulnerable population groups. PROTECT-CH will recruit 9300 residents across 300 UK care homes.
"Lets remember that 30-50% of COVID-19 deaths have occurred in care homes, but care homes are a highly neglected area of research," remarked Dr Philip Bath, professor of stroke medicine, University of Nottingham and lead researcher for PROTECT-CH.
Prof Bath explained that most virus enters the home with staff, relatives, or friends. Despite an effective vaccination campaign, a back-up and additional plan involving antiviral drugs is needed to prevent and treat cases in care homes. "Our vaccines are around 90% effective against the Wuhan variant but may be less so for the Kent and Indian variant, while reduction of transmission is only around 50%," he said, stressing that "vaccines dont work for everyone, and around 8% of residents and 15% of care home staff are not vaccinated".
Two antiviral drugs versus a control group will be assessed in the PROTECT-CH trial with the aim of preventing hospitalisation and mortality. The names of the trial drugs remain confidential currently, but they both have antiviral and anti-inflammatory activity, one is given by inhaler and the other intranasally.
PROTECT-CH takes a post-exposure prophylaxis approach. "We wait for a confirmed infection in the care home before randomisation (cluster randomisation of the whole care home) and treatment," explained Prof Bath, adding that as a platform, new interventions can be added over time.
The primary outcome is comprised of four-levels: no SARS-CoV-2 infection; SARS-CoV-2 infection but resident remains in care home; hospitalisation, and death.
Saye Khoo, professor of pharmacology and therapeutics, University of Liverpool, also runs a platform in the early phase trial area. He is chief investigator for the AGILE Coronavirus Drug Testing Initiative.
AGILE is in the early phase space up to phase 2 of drug development. "[The programme] takes a lot of potential candidates and advances the most plausible at speed and with rigour," he said. "Its an umbrella off which hang various trials of candidate drugs being tested at the same time. It is largely tuned to look at antiviral drugs mainly the game-changers to advance quickly and reject others."
He added that, "Vaccines do the bulk of heavy-lifting, but antivirals are important in managing the disease."
Prof Khoo drew attention to the threat of antiviral resistance without careful use. "Dont bet against the virus becoming resistant. Mutating is their core business and its how they survived for millions of years. We want to get ahead of this virus."
Prof Hall suggested that combination therapies might help prevent the development of resistance. "We have seen viruses develop resistance to other antiviral drugs. For example, by altering their genetic code, an antiviral becomes resistant to protease inhibitors as seen with hepatitis C or HIV, and here we use a combination of two or three drugs to help overcome that. It is currently, a theoretical risk in the long-term in the same way as we see variants escape from the vaccine."
Hazuda agreed but added that resistance was less likely when using an antiviral for an acute infection compared to use in a patient with chronic disease. "But we cant bet against a virus. When we start a drug development programme, it is in our interest to understand the potential for resistance."
Based on a briefing at the Science Media Centre, London, given on Thursday 27 May, 2021.
Smith and Jones report no relevant financial relationships. OR
Smith reports receiving grant funding from Merck. Jones reports no relevant financial relationships. The study was funded by Merck.
Go here to read the rest:
Headway in the Challenge to Develop Two Antivirals Against COVID-19 This Year - Medscape
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022